Tumour Infiltrating Lymphocyte Therapy Hubs for Melanoma
Details
| Contract Title: | Tumour Infiltrating Lymphocyte Therapy Hubs for Melanoma |
| Published Date: | May 20, 2025 |
| Notice Type: | Notice (CompetitiveContractNotice) |
| Value Banding: | Low Value |
| Delivery Point: | United Kingdom |
Description:
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential of many unwarranted side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to ITU....